Dec 15 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX)
VRX.TO
* CEO says will get back to acquisitions, but not next year,
when it will focus on paying down debt instead - CNBC
* CEO says will spend 7 to 8 percent of sales on research
and development in 2016 - about half the level of typical big
pharma companies and up from previous spending - CNBC
* CEO says will spend $400 to $500 million on R&D